 has completed the consolidation of its Molecular Genetic Services (MGS) business at its newly expanded facilities in Manchester.

Gen-Probe Incorporated has expanded its footprint in Wythenshawe, Manchester from 11,000 sq ft to  67,000 sq ft. Among other benefits, the expansion of the facility will provide the catalyst for theconsolidation and further development of a suite of outsourced genomic services. Gen-Probe Life  Sciences Ltd. will further develop its suite of genomic services aimed specifically at the R&D stage of drug  development. These services will provide support to translational research through the discovery,  qualification, and validation of biomarkers and IUO assays with the potential for both drug  development and companion diagnostic applications.  

David Scott, Senior Director, commercial services and Diaclone, said, “We are excited to beimplementing this next stage in the strategic development of our pharma services brand. We believe  that the potential to identify and develop both genomic and proteomic assays for biomarkers at an  early stage presents a real value proposition to biopharmaceutical companies seeking companion  diagnostics.” 

As part of this consolidation, Gen-Probe Life Sciences Ltd. has appointed Dr. Bob Holt as MGS  manager responsible for the growth and development of the MGS business, and Haroon Allybacus as  business development manager for its pre-clinical, clinical, and cGMP drug development services.